EP1569684A4 - Verwendung vonhmgb-fragmenten als entzündungshemmende mittel - Google Patents
Verwendung vonhmgb-fragmenten als entzündungshemmende mittelInfo
- Publication number
- EP1569684A4 EP1569684A4 EP03789973A EP03789973A EP1569684A4 EP 1569684 A4 EP1569684 A4 EP 1569684A4 EP 03789973 A EP03789973 A EP 03789973A EP 03789973 A EP03789973 A EP 03789973A EP 1569684 A4 EP1569684 A4 EP 1569684A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hmgb
- fragments
- inflammatory agents
- inflammatory
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42784602P | 2002-11-20 | 2002-11-20 | |
US42784102P | 2002-11-20 | 2002-11-20 | |
US427841P | 2002-11-20 | ||
US427846P | 2002-11-20 | ||
PCT/US2003/037507 WO2004046345A2 (en) | 2002-11-20 | 2003-11-20 | Use of hmgb fragments as anti-inflammatory agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1569684A2 EP1569684A2 (de) | 2005-09-07 |
EP1569684A4 true EP1569684A4 (de) | 2006-08-02 |
Family
ID=32329191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03789973A Withdrawn EP1569684A4 (de) | 2002-11-20 | 2003-11-20 | Verwendung vonhmgb-fragmenten als entzündungshemmende mittel |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1569684A4 (de) |
JP (1) | JP2006510619A (de) |
AU (1) | AU2003294488B2 (de) |
CA (1) | CA2506328A1 (de) |
NZ (1) | NZ540067A (de) |
WO (1) | WO2004046345A2 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
CN1878793A (zh) | 2003-09-11 | 2006-12-13 | 鉴定医疗有限公司 | 拮抗hmgb1的单克隆抗体 |
JP2008504335A (ja) * | 2004-07-02 | 2008-02-14 | クレアビリス・セラピューティクス・エスピーエー | Hmgb1に関連する病変の治療のための核酸 |
WO2006012373A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
BRPI0514835A (pt) * | 2004-09-03 | 2008-06-24 | Creabilis Therapeutics Spa | variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico |
CN101132811B (zh) * | 2004-10-22 | 2012-05-30 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
WO2006138429A2 (en) * | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
EP1909834A2 (de) * | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Verwendung von hmgb1-antagonisten zur behandlung von entzündungskrankheiten |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
CA2628546A1 (en) * | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
US8546547B2 (en) * | 2006-09-15 | 2013-10-01 | Creabilis Therapeutics S.P.A. | Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1 |
EP2517723B1 (de) | 2006-09-18 | 2019-11-06 | The Board of Trustees of The University of Arkansas | Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen |
WO2008099913A1 (ja) | 2007-02-15 | 2008-08-21 | Kumamoto University | ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤 |
KR20160070169A (ko) | 2008-04-30 | 2016-06-17 | 가부시키가이샤 제노믹스 | 생체내 기능적 세포의 고효율 채취법 |
CA2778759A1 (en) | 2009-10-28 | 2011-05-05 | Genomix Co., Ltd. | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
EP2525817B8 (de) | 2010-01-21 | 2017-09-20 | The Board of Trustees of The University of Arkansas | Impfstoffvektoren und verfahren zur verstärkung von immunreaktionen |
HUE046858T2 (hu) | 2010-06-09 | 2020-03-30 | Univ Arkansas | Vakcina és eljárások campylobacter fertõzés csökkentésére |
CA2834255C (en) | 2011-04-26 | 2021-11-02 | Genomix Co., Ltd. | Peptide for inducing regeneration of tissue and use thereof |
TR201807769T4 (tr) | 2012-10-25 | 2018-06-21 | Genomix Co Ltd | HMGB1 fragmanı kullanılarak spinal kord yaralanmasının tedavi edilmesine yönelik yeni yöntem. |
AU2013335684B2 (en) | 2012-10-25 | 2017-06-29 | Osaka University | Novel method for treating cardiac infarction using HMGB1 fragment |
AU2013375015A1 (en) | 2013-01-28 | 2015-08-13 | Evec Inc. | Humanized anti-HMGB1 antibody or antigen-binding fragment thereof |
MY173328A (en) | 2013-02-14 | 2020-01-16 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
EA033538B1 (ru) | 2013-03-15 | 2019-10-31 | Univ Arkansas | Композиции и способы усиления иммунного ответа на кишечные патогены |
TWI758288B (zh) | 2016-05-03 | 2022-03-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
TWI805565B (zh) | 2017-01-27 | 2023-06-21 | 日商斯德武利姆股份有限公司 | 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物 |
JP2020513808A (ja) | 2017-03-15 | 2020-05-21 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
EP3718561A4 (de) * | 2017-12-01 | 2021-07-21 | Stemrim Inc. | Therapeutikum für entzündliche darmerkrankung |
WO2019156137A1 (ja) * | 2018-02-08 | 2019-08-15 | 株式会社ステムリム | 乾癬の治療薬 |
MX2021003838A (es) * | 2018-10-05 | 2021-05-27 | Res Inst Nationwide Childrens Hospital | Derivados de proteina hmgb1 para la eliminacion de biopeliculas. |
CN111743890A (zh) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | 水绫霉素或其衍生物的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033401A2 (de) * | 1999-02-26 | 2000-09-06 | Genset | Exprimierte Sequenzmarker und kodierte menschliche Proteine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
-
2003
- 2003-11-20 NZ NZ540067A patent/NZ540067A/en not_active IP Right Cessation
- 2003-11-20 CA CA002506328A patent/CA2506328A1/en not_active Abandoned
- 2003-11-20 EP EP03789973A patent/EP1569684A4/de not_active Withdrawn
- 2003-11-20 WO PCT/US2003/037507 patent/WO2004046345A2/en active IP Right Grant
- 2003-11-20 JP JP2004554020A patent/JP2006510619A/ja active Pending
- 2003-11-20 AU AU2003294488A patent/AU2003294488B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033401A2 (de) * | 1999-02-26 | 2000-09-06 | Genset | Exprimierte Sequenzmarker und kodierte menschliche Proteine |
Non-Patent Citations (4)
Title |
---|
DAILEY LISA ET AL: "Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 186, no. 3, March 2001 (2001-03-01), pages 315 - 328, XP002373261, ISSN: 0021-9541 * |
DATABASE Geneseq [online] 6 October 2000 (2000-10-06), "Human secreted protein, SEQ ID NO: 7904.", XP002373264, retrieved from EBI accession no. GSN:AAG03823 Database accession no. AAG03823 * |
ROGALLA P ET AL: "Mapping and molecular characterization of five HMG1-related DNA sequences", CYTOGENETICS AND CELL GENETICS, vol. 83, no. 1-2, 1998, pages 124 - 129, XP009063822, ISSN: 0301-0171 * |
YANG HUAN ET AL: "Reversing established sepsis with antagonists of endogenous high-mobility group box 1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 1, 6 January 2004 (2004-01-06), pages 296 - 301, XP002373262, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003294488A1 (en) | 2004-06-15 |
WO2004046345A2 (en) | 2004-06-03 |
JP2006510619A (ja) | 2006-03-30 |
WO2004046345A3 (en) | 2004-12-02 |
CA2506328A1 (en) | 2004-06-03 |
EP1569684A2 (de) | 2005-09-07 |
NZ540067A (en) | 2007-05-31 |
AU2003294488B2 (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1569684A4 (de) | Verwendung vonhmgb-fragmenten als entzündungshemmende mittel | |
HUP0500042A3 (en) | Use of hmg fragments as anti-inflammatory agents | |
AU2003255482A1 (en) | Use of 4 amino-quinazolines as anti cancer agents | |
AU2003259735A8 (en) | Small-mer compositions and methods of use | |
AU2003285091A1 (en) | Interferon antagonists useful for the treatment of interferon related diseases | |
PL375784A1 (en) | Use of erythopoietin | |
AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
AU2003295336A1 (en) | Use of etodoclac to treat hyperplasia | |
AU2003258662A1 (en) | Use of 4-amino-quinazolines as anti cancer agents | |
AU2003278157A1 (en) | Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists | |
AU2003279841A8 (en) | Uses of human zven antagonists | |
GB2392618B (en) | Compositions for therapeutic use | |
IL165839A0 (en) | Compounds useful for the treatment of cancer compositions thereof and methods therewith | |
PL372655A1 (en) | Compositions of pentafluoropropane | |
GB0218798D0 (en) | Improvements to determination of ovulation | |
PL371427A1 (en) | New uses of substituted aminoalkanephosphonic acids | |
AU2003282510A8 (en) | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents | |
AU2003270202A8 (en) | Pharmaceutical compositions useful for the treatment of cancers | |
AU2003298725A8 (en) | Preparation of metallotexaphyrins | |
AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
AU2003252185A8 (en) | Topical composition for the treatment of scar tissue | |
EP1546326A4 (de) | Neue zusammensetzungen und verfahren zur behandlung von psoriasis | |
AU2003227519A1 (en) | The use of milnacipran for the treatment of tension-type headache | |
AU2003279282A8 (en) | Methods and compositions for the treament of cancer | |
HUP0203929D0 (en) | New use of substituted alkyl-piridazinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050616 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060630 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: O'KEEFE, THERESA, L. Inventor name: NEWMAN, WALTER |
|
17Q | First examination report despatched |
Effective date: 20080818 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081230 |